Brian Mahlon Ross

US Patent:

20070082838, Apr 12, 2007

Filed:

Aug 30, 2006

Appl. No.:

11/513756

Inventors:

Tapas De - Los Angeles CA, US
Neil Desai - Los Angeles CA, US
Andrew Yang - Rosemead CA, US
Zachary Yim - Los Angeles CA, US
Patrick Soon-Shiong - Los Angeles CA, US
Brian Ross - Plymouth MI, US

Assignee:

Abraxis BioScience, Inc. - Los Angeles CA

International Classification:

A61K 31/337
A61K 38/38

US Classification:

514002000, 514449000, 977906000

Abstract:

The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.

US Patent:

20090264732, Oct 22, 2009

Filed:

Oct 11, 2006

Appl. No.:

12/090062

Inventors:

Brian D. Ross - Altadena CA, US
Pratip Bhattacharya - Pasadena CA, US

Assignee:

HUNTINGTON MEDICAL RESEARCH INSTITUTES - Pasadena CA

International Classification:

A61B 5/055

US Classification:

600420

Abstract:

The present invention relates to compositions and methods useful in connection with magnetic resonance imaging. In various embodiments, the invention employs the PASADENA polarization technique to prepare contrast agents that target complementary molecules in the body and/or that are processed through predetermined, natural metabolic pathways. The invention includes methods of using the contrast agents and kits including the same. In one embodiment, a diagnostic and prognostic method relating to Alzheimer's disease is described. Further embodiments relate to medical devices including the contrast agents.

US Patent:

20100092391, Apr 15, 2010

Filed:

Jan 11, 2008

Appl. No.:

12/522443

Inventors:

Brian D. Ross - Altadena CA, US
Pratip Bhattacharya - Pasadena CA, US

Assignee:

HUNTINGTON MEDICAL RESEARCH INSTITUTES - Pasadena CA

International Classification:

A61K 49/10
C07C 229/26
C07C 69/02

US Classification:

424 93, 562563, 560231

Abstract:

Compositions and methods useful in connection with magnetic resonance imaging are provided. Metabolites hyperpolarized by dynamic nuclear polarization are used as reporter molecules in nuclear magnetic resonance (“NMR”) spectroscopy to study metabolic pathways and diagnose disease states. The reporter molecules include hyperpolarized glutamine and hyperpolarized acetate. The invention includes the reporter molecules, compositions including the reporter molecules in pharmaceutically acceptable carriers, methods for studying metabolic pathways that include introducing one or more of the reporter molecules to a mammalian subject and imaging a target substance using NMR spectroscopy, and kits useful in studying metabolic pathways that incorporate one or more of the reporter molecules and instructions for their use.

US Patent:

20100233089, Sep 16, 2010

Filed:

Oct 6, 2008

Appl. No.:

12/680733

Inventors:

Brian D. Ross - Altadena CA, US
Pratip Bhattacharya - Pasadena CA, US

Assignee:

HUNTINGTON MEDICAL RESEARCH INSTITUTES - Pasadena CA

International Classification:

A61K 49/12
A61P 35/00

US Classification:

424 93

Abstract:

A method for imaging genetic material such as DNA, RNA and genes by magnetic resonance imaging incorporating hyperpolarization techniques, such as PASADENA or DNP may be used in various app metabolomics, medical diagnosis and genetic research.

US Patent:

20110095759, Apr 28, 2011

Filed:

Oct 14, 2010

Appl. No.:

12/904941

Inventors:

Pratip BHATTACHARYA - Pasadena CA, US
Brian D. ROSS - Altadena CA, US

Assignee:

HUNTINGTON MEDICAL RESEARCH INSTITUTES - Pasadena CA

International Classification:

G01R 33/48

US Classification:

324307

Abstract:

The present subject matter relates to methods and apparatus for using hyperpolarization to improve imaging. Am exemplary embodiment, a PASADENA polarizer, is capable of delivering 2.5-5 ml of highly hyperpolarized biological C and N imaging reagents in less than one minute, and capable of repeated delivery every 5-8 minutes. Exemplary quality control sequences are also provided to create versatile methods, systems, and apparatuses for a variety of biomolecules, capable of undergoing reaction with parahydrogen necessary for effective PASADENA. The subject matter simplifies the technology for routine liquid state generation of hyperpolarized molecules for C and N subsecond imaging and spectroscopy in vivo and further advance the clinical application of this technology. Methods and systems for providing magnetic shielding are also provided.

US Patent:

20130190606, Jul 25, 2013

Filed:

Jan 25, 2013

Appl. No.:

13/750901

Inventors:

Huntington Medical Research Institutes - Pasadena CA, US
Brian D. Ross - Altadena CA, US

Assignee:

Huntington Medical Research Institutes - Pasadena CA

International Classification:

A61B 5/055
A61B 5/00

US Classification:

600411, 600410

Abstract:

Using both quantitative MRI and quantitative MRS, the inventor demonstrates herein that as age and dementia progress, hippocampal volume (HV), amygdala volume (AV), and NAA/mI ratio all decrease compared to normal controls. The inventor's data also demonstrate herein that NAA/mI vs. total amygdala volume showed a very strong linear correlation, while NAA/mI vs. mean total hippocampal volume had a lesser but still significant correlation. Further, after analyzing the data derived from both quantitative MRI and quantitative MRS methods, the inventor made the surprising discovery that the two tests, when combined, provide significantly improved biomarkers over either alone, and are more effective at early MCI and/or AD diagnosis, as well as HS diagnosis.

US Patent:

56178611, Apr 8, 1997

Filed:

Feb 16, 1994

Appl. No.:

8/197099

Inventors:

Brian Ross - Altadena CA
Thomas Ernst - Gundelfingen, DE
Roland Kreis - Boll, CH

Assignee:

Huntington Medical Research Institutes - Pasadena CA

International Classification:

A61B 5055

US Classification:

1286532

Abstract:

The present invention relates to a method for determining the concentration of metabolites in the brain using magnetic resonance spectrum techniques. The method comprising defining a volume within the brain, obtaining a magnetic resonance spectrum of the defined volume, suppressing the signal from water to reveal the spectra from metabolites, correcting the baseline, obtaining the magnetic resonance spectrum of an external standard, comparing the signal from the metabolites to the signal from the external standard and calculating the in vivo concentration of the metabolites. In one embodiment of the invention a diagnosis for Alzheimer Disease is made by comparing the relative peak heights of myo-inositol relative to creatine and N-acetylaspartate relative to creatine in the patient to the relative peak heights of myo-inositol relative to creatine and N-acetylaspartate relative to creatine for a normal population, wherein an increase in the relative peak height of myo-inositol and a decrease in the relative peak height of N-acetylaspartate is diagnostic of Alzheimer Disease.

US Patent:

20200077925, Mar 12, 2020

Filed:

May 2, 2019

Appl. No.:

16/402183

Inventors:

Wernher Ovalle - Costa Mesa CA, US
Brian Ross - Costa Mesa CA, US

International Classification:

A61B 5/11
A61G 7/05
A61B 5/00

Abstract:

Systems and methods for a bedside handle system having two-stage laser motion detection and wireless communication alert. The system detects and sends wireless alerts when a patient sits up and when the patient stands up. The system further includes a mobile app for receiving and displaying the alerts.